 trial cyclophosphamid doxorubicin vincristin versu cisplatin altern regimen small-cel lung cancer between april may studi standard chemotherapi altern basi patient small-cel lung cancer patient cyclophosphamid dose IV day doxorubicin IV day vincristin IV day cav cisplatin IV day IV day PE PE cav/p regimen week patient studi elig analysi cav PE cav/p respons rate PE cav/p rate cav complet respons rate similar nine patient initi cav regimen contrast patient cav PE regimen regimen non-cross-resist respons durat cav/p cav surviv time cav/p month superior cav month PE month patient limit diseas surviv altern arm superior surviv cav arm surviv PE arm toxic effect accept chemotherapi regimen result chemotherapi standard chemotherapi cav PE differ dramat